Supplementary Figure S5 from Efficacy of a Small-Molecule Inhibitor of Kras&lt;sup&gt;G12D&lt;/sup&gt; in Immunocompetent Models of Pancreatic Cancer

Samantha B. Kemp; Noah Cheng; Nune Markosyan; Rina Sor; Il‐Kyu Kim; Jill Hallin; Jason Shoush; Liz Quinones; Natalie V. Brown; Jared B. Bassett; Nikhil Joshi; Salina Yuan; Molly Smith; William P. Vostrejs; Kia Z. Perez-Vale; Benjamin Kahn; Feiyan Mo; Timothy R. Donahue; Caius G. Radu; Cynthia Clendenin; James G. Christensen; Robert H. Vonderheide; Ben Z. Stanger

doi:10.1158/2159-8290.30849142

Abstract

MRTX1133 exerts in vivo effects early in treatment

Related Publications

Effects of Radiotherapy and Surgery in Early Breast Cancer — An Overview of the Randomized Trials

Early Breast Cancer Trialists' Collaborative Group

Background\nRandomized trials of radiotherapy and surgery for early breast cancer may have been too small to detect differences in long-ter...

1996 New England Journal of Medicine 785 citations

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis , Michael E. Goldberg , Danielle Greenawalt +66 more

Abstract KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups o...

2018 Cancer Discovery 1505 citations

Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

Hira Rizvi , Francisco Sánchez-Vega , Konnor La +29 more

Purpose Treatment of advanced non–small-cell lung cancer with immune checkpoint inhibitors (ICIs) is characterized by durable responses and improved survival in a subset of pati...

2018 Journal of Clinical Oncology 1371 citations

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS -Mutant Cancers

Snjezana Doğan , Ronglai Shen , Daphne Ang +8 more

Abstract Purpose: The molecular epidemiology of most EGFR and KRAS mutations in lung cancer remains unclear. Experimental Design: We genotyped 3,026 lung adenocarcinomas for the...

2012 Clinical Cancer Research 595 citations

Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease

Craig Barr , Chim C. Lang , Jacqueline Hanson +3 more

In chronic heart failure, a diuretic plus an angiotensin-converting enzyme (ACE) inhibitor only partially suppresses aldosterone despite the fact that aldosterone has many harmf...

1995 The American Journal of Cardiology 315 citations

Publication Info

Year: 2025
Type: article
Citations: 0
Access: Closed

External Links

Download PDF (Free) View on DOI.org

Social Impact

Altmetric

Supplementary Figure S5 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

CrossRef

Cite This

APA Style

                            
                                    Samantha B. Kemp, 
                                
                                    Noah Cheng, 
                                
                                    Nune Markosyan
                                
                                et al.
                            
                            (2025). 
                            Supplementary Figure S5 from Efficacy of a Small-Molecule Inhibitor of Kras&lt;sup&gt;G12D&lt;/sup&gt; in Immunocompetent Models of Pancreatic Cancer. 
                            
                            .
                            https://doi.org/10.1158/2159-8290.30849142

Identifiers

DOI: 10.1158/2159-8290.30849142

Data Quality

Data completeness: 70%

Supplementary Figure S5 from Efficacy of a Small-Molecule Inhibitor of Kras<sup>G12D</sup> in Immunocompetent Models of Pancreatic Cancer